New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S. The ...

This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

Experts at Cincinnati Children's report proof-of-concept results that may sharply reduce the risk of a lethal side effect that has negatively impacted the use of revolutionary cancer immunotherapies ...

Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...

Please provide your email address to receive an email when new articles are posted on . Black and Hispanic patients continue to be underrepresented in immune checkpoint inhibitor trials. Almost ...

It often starts with something small—a dark spot on the skin that looks a little off. A dermatologist takes a closer look, runs a biopsy, and soon after, the diagnosis arrives: melanoma. If the cancer ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Please provide your email address to receive an email when new articles are posted on . Glucocorticoids remain the primary option for immune-related adverse events of checkpoint inhibitor therapy in ...